Explore
Validate
LearnMA1-37166
antibody from Invitrogen Antibodies
Targeting: BCL2L1
Bcl-X, bcl-xL, bcl-xS, BCL2L, BCLX, PPP1R52
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [12]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA1-37166 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-Bcl-xL Monoclonal Antibody (7D9)
- Antibody type
- Monoclonal
- Antigen
- Synthetic peptide
- Description
- This antibody is predicted to react with rat based on sequence homology. Heat-mediated antigen retrieval is recommended prior to staining, using a 10mM citrate buffer, pH 6.0, for 10 minutes followed by cooling at room temperature for 20 min. Following antigen retrieval, incubate samples with primary antibody for 30 min at room temperature. A suggested positive control is Hodgkin's lymphoma.
- Reactivity
- Human, Mouse
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 7D9
- Vial size
- 1 mL
- Concentration
- Lot Dependent
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references New diagnostic markers in salivary gland tumors.
Biomarkers in advanced larynx cancer.
Identification of novel target proteins in sebaceous gland carcinoma.
Head and neck squamous cell carcinoma in pregnant women.
Prognostic and predictive markers in medullary thyroid carcinoma.
Biomarkers of parathyroid carcinoma.
MyoD regulates apoptosis of myoblasts through microRNA-mediated down-regulation of Pax3.
Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response?
Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer.
Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
Bcl-2 expression predicts radiotherapy failure in laryngeal cancer.
Schneider S, Kloimstein P, Pammer J, Brannath W, Grasl MCh, Erovic BM
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2014 Jul;271(7):1999-2007
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2014 Jul;271(7):1999-2007
Biomarkers in advanced larynx cancer.
Bradford CR, Kumar B, Bellile E, Lee J, Taylor J, D'Silva N, Cordell K, Kleer C, Kupfer R, Kumar P, Urba S, Worden F, Eisbruch A, Wolf GT, Teknos TN, Prince ME, Chepeha DB, Hogikyan ND, Moyer JS, Carey TE
The Laryngoscope 2014 Jan;124(1):179-87
The Laryngoscope 2014 Jan;124(1):179-87
Identification of novel target proteins in sebaceous gland carcinoma.
Erovic BM, Al Habeeb A, Harris L, Goldstein DP, Kim D, Ghazarian D, Irish JC
Head & neck 2013 May;35(5):642-8
Head & neck 2013 May;35(5):642-8
Head and neck squamous cell carcinoma in pregnant women.
Eliassen AM, Hauff SJ, Tang AL, Thomas DH, McHugh JB, Walline HM, Stoerker J, Maxwell JH, Worden FP, Eisbruch A, Czerwinski MJ, Papagerakis SM, Chepeha DB, Bradford CR, Hanauer DA, Carey TE, Prince ME
Head & neck 2013 Mar;35(3):335-42
Head & neck 2013 Mar;35(3):335-42
Prognostic and predictive markers in medullary thyroid carcinoma.
Erovic BM, Kim D, Cassol C, Goldstein DP, Irish JC, Asa SL, Mete O
Endocrine pathology 2012 Dec;23(4):232-42
Endocrine pathology 2012 Dec;23(4):232-42
Biomarkers of parathyroid carcinoma.
Erovic BM, Harris L, Jamali M, Goldstein DP, Irish JC, Asa SL, Mete O
Endocrine pathology 2012 Dec;23(4):221-31
Endocrine pathology 2012 Dec;23(4):221-31
MyoD regulates apoptosis of myoblasts through microRNA-mediated down-regulation of Pax3.
Hirai H, Verma M, Watanabe S, Tastad C, Asakura Y, Asakura A
The Journal of cell biology 2010 Oct 18;191(2):347-65
The Journal of cell biology 2010 Oct 18;191(2):347-65
Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response?
Wildeman MA, Gibcus JH, Hauptmann M, Begg AC, van Velthuysen ML, Hoebers FJ, Mastik MF, Schuuring E, van der Wal JE, van den Brekel MW
The Laryngoscope 2009 Feb;119(2):316-22
The Laryngoscope 2009 Feb;119(2):316-22
Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer.
Kumar B, Cordell KG, D'Silva N, Prince ME, Adams ME, Fisher SG, Wolf GT, Carey TE, Bradford CR
Archives of otolaryngology--head & neck surgery 2008 Apr;134(4):363-9
Archives of otolaryngology--head & neck surgery 2008 Apr;134(4):363-9
Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.
Bauer JA, Kumar B, Cordell KG, Prince ME, Tran HH, Wolf GT, Chepeha DB, Teknos TN, Wang S, Eisbruch A, Tsien CI, Urba SG, Worden FP, Lee J, Griffith KA, Taylor JM, D'Silva N, Wang SJ, Wolter KG, Henson B, Fisher SG, Carey TE, Bradford CR
International journal of radiation oncology, biology, physics 2007;69(2 Suppl):S106-8
International journal of radiation oncology, biology, physics 2007;69(2 Suppl):S106-8
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
Mita MM, Ochoa L, Rowinsky EK, Kuhn J, Schwartz G, Hammond LA, Patnaik A, Yeh IT, Izbicka E, Berg K, Tolcher AW
Annals of oncology : official journal of the European Society for Medical Oncology 2006 Feb;17(2):313-21
Annals of oncology : official journal of the European Society for Medical Oncology 2006 Feb;17(2):313-21
Bcl-2 expression predicts radiotherapy failure in laryngeal cancer.
Nix P, Cawkwell L, Patmore H, Greenman J, Stafford N
British journal of cancer 2005 Jun 20;92(12):2185-9
British journal of cancer 2005 Jun 20;92(12):2185-9
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of Bcl-xL using a monoclonal antibody (Product # MA1-37166).
